

1 **Title: Patients with sickle cell disease presented dysregulated plasma Rb/K ratio and Gamma-**
2 **glutamyl cycle in red blood cells**

3
4 **Author (s): Shruti Bhatt¹, Amit Kumar Mohapatra², Apratim Sai Rajesh^{3,#}, Satyabrata Meher⁴,**
5 **Pradip Kumar Panda⁵, Ranjan Kumar Nanda^{2*} and Suman Kundu^{1,6*}**

6
7 ¹Department of Biochemistry, University of Delhi South Campus, New Delhi 110021, India

8 ²Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New
9 Delhi 110067, India

10 ³Department of Biosciences and Biotechnology, Fakir Mohan University, Balasore 756019, India

11 ⁴Multi-disciplinary Research Unit, Veer Surendra Sai Institute of Medical Science and Research, Burla,
12 Sambalpur, Odisha, 768017, India

13 ⁵Sri Sri College of Ayurvedic Science and Research, Sri Sri University, Cuttack, Odisha 753015, India

14 ⁶Department of Biological Sciences, Birla Institute of Technology and Science Pilani, K.K.Birla Goa
15 Campus, Goa 403726, India

16
17 ***Correspondence:**

18 Suman Kundu, BITS Pilani, K.K.Birla Goa Campus, Goa 403726 and University of Delhi South
19 Campus, New Delhi 110021, India;

20 Telephone No: +91-832-2580101

21 Email address: suman.kundu@south.du.ac.in; skundu@goa.bits-pilani.ac.in;

22 Ranjan Kumar Nanda, Translational Health Group, International Centre for Genetic Engineering and
23 Biotechnology, New Delhi 110067, India

24 Email address: ranjan@icgeb.res.in

25
26 [#]Present affiliation: COVID-19 laboratory, Department of Microbiology, Veer Surendra Sai Institute of
27 Medical Science and Research, Burla, Sambalpur, Odisha, 768017, India

28
29
30 **Running title: RBC metabolome in sickle cell disease**

31
32
33
34
35
36
37
38

39 **Abstract**

40

41 Patients suffering from sickle cell disease (SCD) present with multifactorial pathology, and a
42 detailed understanding of it may help to develop novel therapeutics. In this study, the plasma
43 elemental (^{24}Mg , ^{44}Ca , ^{57}Fe , ^{63}Cu , ^{66}Zn , ^{77}Se , ^{85}Rb , ^{208}Pb , and ^{39}K) levels of SCD patients
44 (n=10, male: 50%) and control groups (trait and healthy; n=10 each; male: 50%) were profiled
45 using inductively coupled plasma mass spectrometry (ICP-MS). Additionally, comparative
46 global erythrocyte metabolomics of SCD (n=5, male:100%) and healthy controls (n=5,
47 male:100%) were carried out using liquid chromatography-mass spectrometry (LC-MS). SCD
48 patients had higher plasma ^{24}Mg , ^{44}Ca , ^{66}Zn , ^{208}Pb , and ^{39}K levels and lower levels of ^{57}Fe ,
49 ^{77}Se , and ^{85}Rb compared to controls. These changes in elemental levels, with a decreased Rb/K
50 ratio in the SCD group, may explain the observed frequent hemolysis and severe dehydration
51 with oxidative stress in patients. Mass spectrometry analysis of red blood cells (RBCs of SCD
52 (n=5) and healthy controls (n=5) identified 442 unique metabolic features which separately
53 clustered both the study groups in principal component analysis (PCA). A set of 136 features
54 showed differential ($p < 0.05$; \log_2 fold change $> \pm 1$) regulation and was involved in D-
55 glutamine/D-glutamate, sphingolipid, arginine biosynthesis, glutathione and glycine, serine
56 and threonine metabolism. Interestingly, higher pyroglutamic acid levels were observed in the
57 sickle shaped-RBCs indicating a perturbed gamma-glutamyl pathway in SCD patients.
58 Supplementation of the depleted trace metals and targeting the perturbed metabolic pathways
59 in the RBCs of SCD patients may provide avenues for the development of alternate
60 therapeutics.

61

62 **Key words:** sickle cell disease; metabolomics; ionomics; red cells; oxidative stress; mass spectrometry.

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89
90
91
92

Graphical abstract



93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113

114 1. Introduction

115

116 WHO has recognized sickle cell disease (SCD), the first known human molecular disorder, as
117 a global health pandemic. SCD cases are predicted to increase from 300,000 to 400,000 by
118 2050 and the majority (2/3) of it was recorded in Africa and India [1-5]. SCD is caused by a
119 genetic mutation that translates into the substitution of valine by glutamic acid, at the 6th
120 position in the β chain of the hemoglobin molecule leading to a structural variant known as
121 Hemoglobin S (HbS) [6-8]. HbS has a reduced oxygen affinity, and deoxygenation near tissues
122 leads to exposure of hydrophobic sites on individual T-state HbS molecules [9].

123 Exposed hydrophobic sites act as a nucleus on the HbS molecule, aggregating and
124 forming a 14 nm fiber leading to the sickle shaped RBCs (SS-RBCs). SS-RBCs block the blood
125 vessels leading to an impaired blood supply to organs causing recurrent episodes of acute pain
126 (vaso-occlusive crisis: VOC) and chronic damage leading to poor survival [10-14].
127 Understanding the detailed pathophysiology of SCD at the molecular and elemental level will
128 be useful to identify targets for better clinical management [15].

129 Multi-omics studies using liquid chromatography and inductively coupled plasma mass
130 spectrometry (LC-MS/ICP-MS) are useful to capture the metabolites and elemental details to
131 better understand the disease pathophysiology. Several metabolomic studies have advanced
132 our understanding of various disease pathobiology and have become backbone for the
133 development of alternative therapeutics [16]. Metabolite profiling deciphered that enhanced
134 ADORA2B signaling led to increased plasma adenosine levels, contributing to multiple SCD-
135 related complications [17]. It also captured an enhanced level of circulating sphingosine-1-
136 phosphate (S1P), a bioactive lipid, in both SCD mice and humans [18]. The Sphk1-led S1P
137 increase reprogrammes the metabolic balance via the release of glycolytic enzymes in the
138 cytosol [19], towards the Embden Meyerhoff pathway (EMP) rather than the Hexose
139 monophosphate pathway (HMP) [20]. The metabolic switching induces sickling via elevated
140 production of 2,3-BPG (2, 3 biphosphoglycerate) [21], signals inflammation and tissue
141 damage via the S1PR1 (S1P receptor 1) receptor on immune cells (myeloid lineage) [22]. A
142 dysregulated Land's cycle, evident from increased lysophosphatidylcholine and arachidonic
143 acid levels in SS-RBC, was reported using comparative blood metabolomic profiling of Sickle-
144 Tg mice [23]. Interestingly, these few unbiased metabolic analyses have delivered a massive
145 thrust to in-vitro, pharmacological, preclinical and human studies targeting the ADORA2B and
146 SphK1–S1P–S1PR1–IL-6 signaling cascades to decipher alternative therapeutic strategies
147 [24]. For example, PEG-ADA (adenosine deaminase deficiency), a clinically relevant drug used
148 to treat ADA-deficient patients, reduced elevated adenosine levels, sickling, splenomegaly,
149 multiple tissue damage, and pain [17]. Alternatively, a decrease in adenosine production can
150 be achieved via CD73 inhibitor [e.g., adenosine 5'-(α,β -methylene) diphosphate], reduced
151 sickling and multiple organ damage [25].

152 Similarly, a molecular antagonism of ADORA2B and SphK1 by PSB1115 and PF543,
153 respectively, potently decreases sickling, inflammation and pain [26, 27]. However, only a
154 fraction of these limited studies explored the metabolic profile of SS-RBCs derived from SCD
155 patients [28-30]. Most have been performed on erythrocytes derived from cultured human
156 RBCs and SCD-transgenic mice. Additionally, the previous studies fall short of capturing
157 comprehensive pathological effects of sickle cell haplotypes including Senegal (SEN), Benin
158 (BEN), Bantu or Central African Republic (CAR), Cameroon (CAM) and Arab-Indian
159 (ARAB/AI) that represent the ethnic group or geographical region from which patients
160 originated. To the best of our knowledge, no such investigation has been reported for Indian
161 SCD diaspora. Thus, it would be interesting to investigate metabolic fingerprint of SS-RBCs
162 (primarily Arab-Indian haplotype).

163 Furthermore, it has been repeatedly pressed that multi-omics can supplement and
164 support pathophysiological understanding of various physiological stress [31]. Morphological,
165 biochemical and metabolic changes/alterations induced by multiple pathological conditions
166 can be correlated to the alterations in the concentration of elements in biofluids. The most
167 notable example links RBC clearance with intracellular calcium levels [32, 33]. However, few
168 studies establish the impact of stressors on the homeostatic loss of ions associated with SCD
169 [34-36]. Inductively-coupled plasma mass spectrometry (ICP-MS) is a recent evolution of a
170 decades-old analytical technique to measure elements at trace levels in biological fluids [37].

171 Thus, sparse and restricted reports on the perturbed metabolic pathways in RBCs and
172 plasma elemental levels in SCD patients forged an exciting research avenue to be explored [29,
173 38-40]. In this study, a comparative plasma elemental composition was monitored between
174 SCD and control (traits and healthy) groups and global RBC metabolome profiling between
175 SCD and healthy controls was performed. This study provides an unique opportunity to
176 integrate metabolomic and ionic fingerprints to understand dysregulated metabolic
177 pathways and identify markers associated with SCD. The lack of validated biomarkers for SCA
178 severity represents a void in the state of knowledge of SCD that creates a critical roadblock in
179 the design of clinical trials, the development of novel therapies and the emergence of precision
180 medicine for SCD patients.

181

182 **2. Materials and Methods**

183 **2.1 Ethics statement**

184 All participants provided informed consent before participating in the study. This study was
185 approved by the Institutional Ethics Committee of Sri Sri University, Cuttack, Odisha
186 (SSCASRH/IEC/006/21) and University of Delhi South Campus, Delhi, India
187 (UDSC/IEC/2021/Project/5.10.2021/4). The human studies reported in this study abide by the
188 Declaration of Helsinki principles.

189 **2.2 Study participants**

190 For this study, blood samples were collected from a cohort of ten adult SCD patients with
191 hemoglobin SS (HbSS, n=10, male 50%) disease (Supplementary Table S1), sickle cell trait
192 individuals (hemoglobin AS: HbAS, n=10, male 50%) and ten healthy adults (controls, HC,
193 n=10, male 50%). Written informed consent was obtained from all patients and controls. All
194 protocols and procedures were approved by institutional ethics committees of the collaborating
195 institutes handling patient samples.

196 **2.3 Sample collection and processing**

197 For this study, blood samples were collected from SCD patients in EDTA with hemoglobin SS
198 disease and healthy adults (controls). Complete blood count (CBC) determined the clinical
199 profile of participants; cellulose electrophoresis, PCR, and HPLC are presented in
200 Supplementary Tables 1 and 2. The participants were enrolled according to the approved
201 inclusion and exclusion criteria with consent (S.1.2). The inclusion criteria were a confirmed
202 diagnosis of sickle cell disease by HPLC. Individuals who had received a transfusion were
203 excluded from the study. All patients were receiving analgesic treatments. Blood samples,
204 taken from patients with SCD, were characterized by their sickling properties [41]. Blood tubes
205 were then centrifuged at 2000 ×g for 10 min to separate the RBCs and plasma and were
206 aliquoted into equal volumes (0.5 ml). Plasma samples were stored in a -80 °C freezer until
207 analysis. Samples were processed according to a biphasic liquid-liquid extraction (LLE)
208 protocol. Briefly, RBC metabolism was quenched by extracting metabolites into
209 methanol/water/chloroform solvents.

210 **2.3.1 Untargeted metabolite profiling of sickle RBCs**

211 The 0.5 ml aliquots of human donor erythrocytes (Sri Sri University) that had been pre-treated
212 with heparin anti-coagulant were placed in 2.0 ml microcentrifuge tubes (MCT). After adding

213 internal standards, they were centrifuged at 1000 ×g and 4 °C for 2 min and then placed on ice
214 while the supernatant was aspirated. The RBCs were washed twice with their resuspension in
215 1x phosphate-buffered saline (PBS) through centrifugation, and finally the supernatant was
216 aspirated to leave an RBC pellet. These wash cycles remove non-erythrocytic metabolites and
217 other compounds that may still be present outside the cells; however, it also delays quenching,
218 and might leave residual traces of phosphate salts.

219 **2.3.2 Metabolite extraction**

220 To the RBC pellet of each tube, 0.15 mL of ice-cold, ultrapure water (Milli-Q Millipore,
221 Mississauga, Canada) was added to resuspend the erythrocytes. The tubes were first plunged
222 into the dry ice for 30 seconds followed by 20 seconds of incubation in the water bath at 37 °C
223 to quench metabolism and lyse the cells. After quenching with dry ice, 0.6 ml of methanol at
224 20 °C temperature was added, and the tubes were then vortexed to ensure complete mixing.
225 The tubes were then plunged again into dry ice where 0.45 ml of chloroform was added to each
226 tube. These tubes were vortexed briefly every 5 min for 30 min, and between each brief
227 vortexing interval, they were placed in a cold bath. After 6 brief vortexes, the tubes were
228 transferred to room temperature and 0.15 ml of ice-cold, ultrapure water (Milli-Q Millipore,
229 Mississauga, Canada) was added to drive the phase separation between methanol and
230 chloroform. The tubes were centrifuged at 1,000 ×g for 2 min at 4 °C so that a clear separation
231 of the two phases could be observed above and below the compact disk of erythrocytes. After
232 centrifugation, the tubes were transferred to a -20 °C freezer for an overnight incubation to
233 allow residual chloroform to precipitate out of the aqueous methanol phase. The two liquid
234 phases in each tube were transferred to separate 1.5 mL microcentrifuge tubes without
235 disturbing the compact disk of erythrocytes or transferring any erythrocytes to the new tubes.
236 The final volumes translated to a methanol/water/chloroform ratio of 4:2:3 for extraction and
237 phase separation. The samples were then dried with speed-vac and resuspended in 0.2 mL LC
238 mobile phase (97.9% ultra-pure water / 2% acetonitrile / 0.1% formic acid) [42].

239 **2.3.3 UPLC-Q-Exactive Plus Orbitrap MS/MS analysis**

240 All the samples were analyzed using an UHPLC system (UHPLC Dionex UltiMate® 3000,
241 Dionex, Thermo Fisher Scientific, United States) that was controlled with Thermo Xcalibur
242 software (Thermo Fisher Scientific, United States). The samples were separated using a
243 Kinetex UPLC C18 column (100 × 2.1 mm, 1.9 μm; Phenomenex, Torrance, CA, United
244 States). The mobile phase consisted of solvent A (0.1% formic acid) and solvent B (acetonitrile
245 with 0.1% formic acid). Gradient elution was applied using the following optimized gradient
246 program: A 35-min gradient at a flow rate of 0.3 ml/min with the following conditions was
247 used for separation: 0–5 min, 1% B; 5–10 min, linear gradient from 1–3% B; 10–18 min, linear
248 gradient from 3–40% B; 18–22 min, linear gradient from 40–80% B; 22–27 min, column
249 cleaning at 95% B; and 27–35 min, re-equilibration at 1% B.

250 Mass spectrometry was performed on a Q-Exactive Plus™ Quadrupole-Orbitrap mass
251 spectrometer (Thermo Fisher Scientific, United States) in positive ion mode. Data-dependent
252 acquisition method was used for MS/MS of small molecules in the extractions. The complete
253 MS settings were 70,000 resolution, 1e⁶ AGC (Automatic Gain Control), 100 ms max inject
254 time, and 100–1500 m/z. The MS/MS settings were 35,000 resolution, 1e⁵ AGC, 100 ms max
255 inject time, 1.0 m/z isolation window, and 30 dynamic exclusions. Three technical replicates
256 were run for each extraction, and each technical replicate used a different HCD collision energy
257 (25, 30, and 35, respectively).

258 Compound Discoverer™ 3.0 (Thermo Fisher Scientific, United States) software was used to
259 analyze the LC-MS/MS data for each extraction in positive ion mode.

260 Data normalization and analysis were carried out using MetaboAnalyst 5.0
261 (www.metaboanalyst.ca) [43]. Data exclusion was performed for metabolites with constant
262 values across metabolites and interquartile filtering. Missing values were mean imputed, and

263 normalization was performed. For univariate analysis, fold change and T-test values were
264 calculated, followed by multiple testing correction based on false discovery rate (FDR). ROC-
265 curve (receiver operating characteristic) analysis was also carried out for each metabolic
266 feature, and 95% confidence intervals were calculated using bootstrapping with 1000
267 permutations. Multivariate exploratory analysis was performed using principal component
268 analysis (PCA) and orthogonal projections to latent structures discriminant analysis (OPLS-
269 DA). Permutation testing for OPLS-DA was applied to evaluate model stability to parameter
270 addition. Linear support vector machine (SVM) classifiers were built to predict group class
271 using Monte-Carlo cross-validation (MCCV) and balanced subsampling. A total of six SVMs
272 with an increasing number of metabolites (maximum 100) were compared. Model evaluation
273 was performed using ROC curves, and biomarker identification was achieved using the feature
274 ranking method implemented in SVM (S.2.2, Fig. S3a, b, c).

275 **2.4 Trace metal quantification using inductively coupled plasma mass spectrometry (ICP- 276 MS)**

277 Plasma samples of study groups were processed and subjected to ICP-MS to quantify ^{24}Mg ,
278 ^{44}Ca , ^{57}Fe , ^{63}Cu , ^{66}Zn , ^{77}Se , ^{85}Rb , ^{208}Pb , and ^{39}K . Plasma samples (100 μl) were transferred to
279 MG5 vials (Anton Paar, Graz, Austria), and HNO_3 (250 μl , 70%, #225711 Sigma Aldrich, St.
280 Louis, Missouri, United States, with $\geq 99.999\%$ trace metal basis) and H_2O_2 (50 μl , 30%, 231
281 #1.07298.1000, Supelco, Inc. Bellefonte, Pennsylvania, USA) were added. Vials were sealed
282 using sealers (#411860, Anton Paar). The vials containing the reaction mixtures were digested
283 using a microwave digestion system (Anton Paar, Graz, Austria) ramped up to 300 W in 15
284 min, where it was held for 10 min. The digested samples diluted using trace metal-free water
285 (18.2 $\text{M}\Omega \times \text{cm}$) for inductively coupled plasma mass spectrometry (ICP-MS)
286 analysis. Digested samples were analyzed using ICP-MS (iCAPTM TQ ICP-MS, Thermo
287 Scientific, USA). Thermo Scientific Qtegra Intelligent Scientific Data Solution (ISDS)
288 software was used for operating and controlling the instrument. The ICP-MS was calibrated
289 using a multi-element standard mix (#92091, Sigma Aldrich, St. Louis, Missouri, United
290 States) prepared in 1% HNO_3 per the manufacturer's instruction. Calibration plots were
291 prepared at 1 ppb to 5 ppm concentrations and showed $R^2 = 0.99$. Digested samples were
292 aspirated using a V-grooved MicroMist DC nebulizer and spray chamber of ICP-MS using a
293 sample capillary (0.55 mm). Samples were then passed through a quartz torch with an injector
294 having a diameter of 2 mm. Here, plasma ionized samples passes through sample cones,
295 followed by a skimmer cone. The experiments were conducted in KED (Kinetic energy
296 dissociation) mode to avoid any polyatomic ion interference. During the run, the nebulizer flow
297 was set at 1.04 l/min with a pressure of 3.20 bar. The peristaltic pump revolved clockwise at
298 40 rpm. The quartz torch produced plasma and the exhaust was maintained at 0.49 mbar.
299 Interface temperature was maintained at 29.98°C with a N_2 flow of 14 l/min. The system's
300 sample and skimmer cones were made of nickel with orifices of 1 mm and 0.5 mm,
301 respectively. Between sample runs, HNO_3 (1%) was pumped through the nebulizer with a
302 wash-out time of 30 sec to remove any carryover. The complete experiment was carried out
303 with a dwell time of 0.1s. The average of three runs for each element concentration was
304 calculated and exported for further statistical analysis. Comparative trace element levels
305 between study groups (HbSS, HbAS and HbAA) were calculated considering the limit of
306 detection and dilution factors.

307 **2.4.1 Statistical analysis**

308 An unpaired t-test was performed using Graphpad prism 8 to identify group-specific variations
309 and a $p < 0.05$ was selected as significant.

310
311
312

313 3. Results

314

315 3.1 Clinical characteristics of the study participants

316 In this case and control study, a total of 30 study participants belonging to SCD as case and
317 control (sickle cell trait and healthy controls) were used for plasma ionic and RBC
318 metabolomic profiling. The demographic and clinical characteristics of study participants are
319 presented in Supplementary Tables S1 and S2.

320

321 3.2 Sickle cell anemia is associated with an altered ionic profile

322 From the comparative plasma trace element analysis, significantly higher plasma levels of Mg
323 ($p < 0.0001$), Zn ($p < 0.0001$), Ca ($p < 0.01$), Pb ($p < 0.01$), and K ($p < 0.01$) were observed in SCD
324 patients compared to healthy controls (Fig. 1a, c, d, e, h). Significantly lower plasma levels of
325 Fe, Se ($p < 0.05$), and Rb ($p < 0.01$) were observed, indicating higher oxidative stress in SCD
326 patients (Fig. 1b, g and i). However, Cu levels were similar between study groups (Fig. 1f).
327 Overall, the subjects with sickle cell trait had comparable trace metal levels to the healthy
328 controls except for Rb whose levels hovered in between the levels observed in SCD and healthy
329 control (Fig. 1i). We found that there was a steady decrease in Rb/K levels in the SCD group
330 compared to the healthy controls (Fig. 1j)

331

332 3.3 Metabolomics profiling of RBCs of patients with SCD demonstrated significant 333 deregulation of specific metabolites compared to the healthy controls.

334 Global metabolomic profiling of RBCs from SCD patients and healthy donors yielded 442
335 metabolite features. Principal Components Analysis (PCA) analysis of these analytes showed
336 separate non-overlapping clusters of SCD and healthy groups. The principal components 1 and
337 2 explained 44.2% of the total variance (Fig. 2a). A supervised OPLS-DA model was evaluated
338 to identify significant differentially abundant metabolites between groups and validated using
339 permutation tests (Fig. S2a). A random permutation test ($n = 2000$) resulted in an interpretation
340 rate (R_2) and prediction ability (Q_2) of 0.999 and 0.891, respectively (Fig. S2b). A set of 10
341 analytes (S.2.2, Fig. S2c) qualified the variable importance in projection (VIP) scores > 1.0 and
342 were identified as important metabolites. These metabolites displayed significantly different
343 concentrations between groups, with fold changes > 1.0 or < 0.5 . In the univariate analysis, 136
344 showed differential expression (62/56; up-/down-regulated; $FC >$; $p < 0.005$) in SCD (Fig. 2b,
345 Table S3 and Table S4). After false discovery rate adjustment, 18 analytes (7/10; up/down
346 regulated) showed significant deregulation. In the RBC of SCD patients, glutathione,
347 aminolevulinic acid, DL-2-aminooctanoic acid, D-glutamine, and amino adipic acid (Table S3)
348 levels were significantly high. Significantly lower levels of N6,N6,N6-trimethyl-L-lysine,
349 dihydrothymine, pyroglutamic acid, 2'-alpha-mannosyl-L-tryptophan and 2-aminoisobutyric
350 acid were observed in the RBC of the SCD patients compared to healthy controls (Fig. 2b, 2c).
351 Hierarchical clustering analysis was performed to identify top 25 significantly dysregulated
352 metabolic features in SCD and healthy control (Fig. 2c). The SVM model evaluation
353 highlighted the common metabolic features (Fig. S3c) with the OPLS-DA (Fig. S2c) and
354 hierarchical clustering analysis (Fig. 2c), i.e., thiazolidine-4-carboxylic acid, N-[(3-exo)-8-
355 Benzyl-8-azabicyclo[3.2.1]oct-3-yl]-2-methylpropanamide, ethyl-3-phenylpropionate,
356 meprobamate, N-BOC hydroxylamine. Interestingly, amongst the common metabolic features,
357 thiazolidine-4-carboxylic acid and its derivatives have been reported reduce oxidative stress
358 induced cell death [44].

359

360 3.4 Functional pathway analysis

361 The significantly dysregulated metabolites in SCD group were selected for the KEGG pathway
362 analysis using MetaboAnalyst (<https://www.metaboanalyst.ca>). D-glutamine and D-

363 glutamate metabolism (p-value = 0.0006, Fig. S6a), aminoacyl-tRNA biosynthesis metabolism
 364 (p-value = 0.0009), sphingolipid metabolism (p-value = 0.0009), arginine biosynthesis (p-value
 365 = 0.00099), glycine, serine and threonine metabolism (p-value = 0.004, Fig. S6b), beta-alanine
 366 metabolism (p<0.005), arginine and proline metabolism (p<0.007), glutathione metabolism
 367 (p<0.009, Fig. S6c), glutathione metabolism (p<0.01), and ether lipid metabolism (p<0.012)
 368 were significantly altered in the RBC of SCD patients compared to the control group (Fig. 2d).

369

370 4. Discussion


371

372 The overwhelming significance of RBCs stems from the enormous abundance of hemoglobin.
 373 Any alteration in structural and functional attributes of hemoglobin can translate into
 374 irregularities in RBC functions. These irregularities can have different clinical complications

375

376

377



378

379

380


381 **Figure 1. Plasma trace element levels of sickle cell patient (HbSS), sickle cell trait (HbAS)**
 382 **and healthy control (HC) and their ratio showed significant differences. a) Mg, b) Fe, c)**
 383 **Ca, d) Zn, e) Pb, f) Cu, g) Rb, h) K, i) Se, j) Rb:K. *p < 0.05, **p < 0.01, ***p < 0.001 ****p**
 384 **< 0.0001; HbSS: Sickle cell disease; HbAS: Sickle cell trait; HC: Healthy control.**

385

386 inside the human body [45-47]. The RBCs are designated as a simple model to study cellular
 387 mechanisms due to less epigenetic, transcriptional and translational complications to regulate
 388 the cross-talk amongst various pathways [48-50]. However, recent omics studies highlight the
 389 existence of a complex network of cytosolic enzymes which regulate the energetics and
 390 functioning of RBCs [51, 52]. Physical and pathological stresses can alter the metabolic
 391 equilibrium and accelerate disease progression. Thus, an in-depth understanding is required to
 392 deconstruct the highly interlinked stressed RBC pathophysiology [53].

393 Enhanced hemolysis observed in SCD patients might be contributing to the observed
 394 higher plasma Mg level ($p < 0.001$) [54]. This finding is in agreement with observations by
 395 Olukoga, A. O et al. (1990) [55] which establishes a negative correlation between erythrocyte
 396 and plasma Mg in the SCD cohort [56]. In contrast, low serum Mg levels have been reported
 397 in SCD patients due to Mg homeostasis [57, 58].

398
 399



400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417

418 **Figure 2. Perturbed RBC metabolic fingerprint observed in sickle cell disease patients (HbSS)**
 419 **compared to the healthy control (HC).** a) PCA score plot showed RBC metabolites (n=442) of SCD
 420 patients cluster away from the healthy controls. b) Volcano plot highlighting the dysregulated
 421 erythrocyte metabolites in SCD (HbSS) compared to the healthy control (HC). c) Hierarchical
 422 Clustering representing the distribution of 25 important RBC metabolites in SCD patients and healthy

423 controls. Columns correspond to samples, and rows to individual metabolites. The color scale indicates
424 the relative abundance of metabolites: red being the most abundant and blue the less abundant
425 metabolites. d) Metabolic pathways altered in the RBCs of SCD patients compared to healthy controls.
426 The pathway impact values (x-axis) represent the influencing factor of topological analysis, and the $-\log(p)$
427 (y-axis) represents the p-value of the pathway enrichment analysis. The vital metabolic pathways
428 were defined as having $-\log(p) > 2$ and pathway impact factor > 0.2 .

429

430 Similarly, RBCs contain 10-15% of the total cellular pool of calcium. Sickle cells show
431 increased Ca as compared to normal cells in the oxygenated state [59]. Malinovská V et al.
432 (1991) reported that stress conditions increase plasma Ca levels [60]. Higher plasma Ca levels
433 as observed in SCD patients can be attributed to frequent hemolysis due to prolonged stress in
434 SCD patients [61]. However, in SCD an accumulation of intraerythrocytic Ca has been reported
435 due to malfunction of Ca^{2+} transporters [33]. Higher plasma Ca levels as observed in SCD
436 patients can be attributed to frequent hemolysis due to prolonged stress in SCD patients [62].
437 An increased intracellular Ca concentration induces alteration to calcium-sensitive potassium
438 (K^+) channel protein 4 (also known as the putative Gardos channel and $\text{K}-\text{Cl}$ cotransporter 1
439 (KCC1), KCC3 and/or KCC4 [63], resulting in potassium-efflux and decreased cell volume
440 [64-66], which in turn increases the stiffness of RBC. Similarly, we also observed higher
441 plasma K levels corroborating earlier reports [67-71]. Thus, K^+ is an important indicator of
442 SCD, however, its measurement to assess the severity in many pathophysiological conditions
443 can be erroneous due to factors like pseudohyperkalemia and poses a challenge [72].

444 Another similar group I alkali metal, rubidium (Rb^+) was significantly lower ($p < 0.01$)
445 in SCD patients compared to the trait and control group. It shares similar biochemical
446 properties and readily exchanges with K^+ and thus, can be a useful proxy for K^+ . Although its
447 biological function still needs further understanding, ^{86}Rb 's prominent presence was utilised to
448 measure basal metabolic rate, establishing a correlation between its radioactive turnover and
449 K^+ concentration [73]. We are the first to report a correlation between plasma Rb and K^+
450 concentration, which significantly decreased from healthy to trait and even decreased further
451 in the SCD group. Rb may have the potential to be used as a marker to assess the severity
452 associated with sickling. Rb has unique neurophysiological and neuroprotective properties [74-
453 76]. Kordjazzy et al. (2015) found that mice administered with Rb showed less depression-like
454 behaviour through changes in the hippocampus [77]. Recent clinical trials and studies have
455 widely reported that SCD patients suffer from neuro-cognitive complications [78-80].
456 Neurocognitive impairment have been reported in children with SCD, which affects their
457 visuo-spatial memory (14.8%), IQ (85.4%) and copying (68.2%) [79, 81, 82]. These studies
458 indicate that SCD can lead to the development of neuro-complications. Thus, Rb's beneficial
459 role in improving SCD patients' neurocognitive complications can be further explored.

460 We observed significantly higher plasma lead levels in SCD compared to the trait and
461 healthy cohort. These findings align with previous studies that have correlated BLL (Blood
462 lead level) levels with moderate and severe anemia [83]. In addition to neurological toxicity,
463 Pb can worsen sickle cell anemia by impairing heme synthesis and increasing the rate of red
464 blood cell destruction [84]. Schwartz et al (1982) showed a dose-dependent increase in anemia
465 in children with blood lead levels near $25 \mu\text{g}/\text{dl}$ [83, 85]. A linear decrease in hemoglobin was
466 reported in children with increased BLL (BLL $> 30 \mu\text{g}/\text{dl}$) by Drossos et al (1985) [86].
467 Although these findings indicate a relationship between Pb levels and SCD, a more detailed
468 analysis is required to solidify these claims.

469 High plasma Zn levels of the SCD group was observed compared to trait and control
470 group that does not corroborate with earlier reports [34, 87]. An increased iron (Fe)
471 concentration in the intestinal lumen may antagonize the uptake of Zn [88]. Zn concentrations
472 have been inversely correlated to Copper (Cu) levels [87, 89]. This depletion of Cu could
473 impair iron absorption [90]. However, no such relationship was observed in our present study

474 and no significant change in Cu levels was observed across the group. On the contrary, a steady
475 Fe increase was observed in trait and healthy group ($p < 0.05$), which indicates disrupted Fe
476 homeostasis and most often caused by excessive urinary loss of iron as reported by some
477 studies [91, 92].

478 Selenium (Se) is an essential component of mammalian enzymes like glutathione
479 peroxidases (GPx) [93, 94], providing antioxidant defence against ROS. Erythrocytes of Se-
480 deficient rats failed to protect hemoglobin from oxidative damage in the presence of ascorbate
481 or H_2O_2 or glutathione [94]. Se deficiency is known to alter erythroid parameters like RBC,
482 HCT, HGB, and MCHC ($P < 0.05$) and makes erythrocytes osmotically fragile [95]. The family
483 is involved in oxido-reduction reactions and these reactions occur in diverse tissues and
484 physiological pathways. Se supplementation has preventive and therapeutic role in diverse
485 disease conditions [96-100]. Plasma Se levels were highest in the healthy and lowest in the
486 SCD group ($p < 0.05$); so Se supplementation may be beneficial to SCD patients.

487

488 **4.1 Metabolic insights in sickle RBCs indicate an altered Gamma-Glutamyl cycle which** 489 **fuels ATP depletion from sickle red blood cells**

490 The main oxidative damage control system in RBCs, the glutathione pathway, has been
491 reported to be altered in HbS red blood cells [101]. There is increasing evidence that this
492 alteration leads to oxidative stress with a negative domino effect on the pathophysiology of
493 SCD [61]. ROS can be derived non-enzymatically (Fenton chemistry) from denatured sickle
494 hemoglobin (Hb S) moieties and lipid peroxidation or derived enzymatically by the action of
495 NADPH oxidase. ROS damage RBC membranes and decrease cell deformability, which
496 contributes to the pathophysiology of SCD [102]. Plasma-free hemoglobin (Hb) and iron
497 chelates are by-products of hemolysis that can also act as oxidants [103]. To counteract ROS,
498 mammalian cells have antioxidant pathways involving reduced glutathione (GSH), NAD(H),
499 NADP(H), glutamine and nitric oxide (NO), which are complex and interlinked. Glutathione
500 exists in a reduced (GSH) and oxidized (GSSG) form. The thiol reductant, GSH, scavenges
501 ROS such as hydrogen peroxide and lipid peroxides [103, 104]. GSH can also interact with Hb
502 to form glutathiol-hemoglobin (G-Hb) which reduces the propensity for sickling
503 [105]. Similarly, we observed alterations in glutathione pathway along with disruptions in
504 glutamine/glutamate metabolism, which are the main oxidative damages control system in
505 RBCs of HbS cells.

506 Significant disruptions in glycine, serine, and threonine metabolism with lower 5-
507 aminolevulinate levels (p -value < 0.01), which is a by-product of glycine, indicate lower glycine
508 levels (Fig. 3, Fig. S6c). Chronic oxidative stress leads to increased GSSG efflux that exceeds
509 the rate of GSH synthesis [106]. However, rapid efflux of GSSG leads to NADPH depletion,
510 which was observed in our study. Thus, de novo GSH synthesis becomes critical in these
511 oxidative stress conditions and needs glycine, glutamate, and cysteine in an ATP-dependent
512 biosynthesis. Catabolism of GSH via membrane mounted gamma-glutamyl transpeptidase
513 (GGT) followed by removal of gamma-glutamyl moiety from GSH by gamma-glutamyl
514 transpeptidase yields cysteinyl-glycine conjugates (Cys-Gly) and g-glutamyl-amino acid (G-
515 Glu) as products. Hydrolysis of these conjugates by ectoprotein dipeptidases (DPT) yields
516 cysteine and glycine. The g-Glu, glycine and cysteine enter the cell through specific
517 transporters. The g-glutamyl with an amino acid derivative enters the cell and gamma-glutamyl
518 cyclotransferase (γ -GCT/GGCT) converts to 5-oxoproline and the corresponding amino acid.
519 5-oxoprolinase (OXP) converts 5-oxoproline (pyroglutamic acid) to glutamate in a ATP
520 dependent manner. Oxoproline is converted to a dipeptide i.e. g-glutamylcysteine by
521 combining glutamate and cysteine by gamma-glutamylcysteine synthetase (γ -GCS/G-GCS) in
522 a two-step reaction which utilizes an ATP per catalytic step. This g-glutamyl cysteine can either
523 act as substrate for GGCT to recycle to 5-oxoproline or it can be converted to GSH by the

524 addition of glycine through GSH synthetase (GS) activity with the usage of an ATP molecule
525 [106-108].

526 ATP production and antioxidant systems within the RBC exploit Hb-based O₂-transport
527 to respond to various physiologic and pathophysiologic stresses. RBCs produce energy through
528 the hexose monophosphate pathway (HMP) and glycolysis, only via the Embden–Meyerhof
529 pathway (EMP), which generates ATP [109]. The HMP route produces NADPH, which powers
530 the thiol-based antioxidant system critical for maintaining homeostasis in the O₂-rich RBC
531 [110]. For example, O₂ offloading promotes glycolysis to generate both 2,3-BPG (a negative
532 allosteric effector of Hb O₂ binding) and ATP. Dynamic regulation of ATP ensures the
533 functional activity of ion pumps, cellular flexibility, drives metabolic reactions and vaso
534 regulation/dilation under hypoxic stress (Fig. 3). A toggle between frequency of EMP and HMP
535 is regulated by the assembly of an EMP protein complex upon the cytoplasmic domain of the
536 band 3 membrane protein [cdB3, also known as anion exchanger 1 (AE1)] [111-118].
537 Metabolite flux through EMP vs. HMP oscillates depending on the Hb conformation
538 (oxygenation state) and cdB3 phosphorylation. RBC deoxygenation promotes the generation
539 of ATP, while full oxygenation of RBCs promotes NADPH generation [109, 119]. Rogers and
540 co-workers (2009) showed that RBC antioxidant systems fail when HMP flux is blunted by
541 altered cdB3 protein assembly/phosphorylation caused by aberrant Hbs or hypoxia [109, 120,
542 121].

543 SS-RBCs are characterized by elevated indices of oxidative stress and depressed ATP
544 levels[122], as well as elevated 2,3-DPG. Recently published evidence suggests a role for
545 pannexin 1 (Px1) in the release of ATP from RBCs due to Gi protein stimulation in SCD [123,
546 124]. Zhang et al. (2011) showed that an elevated level of plasma adenosine plays a role in the
547 increased concentration of DPG, which contributes to SCD pathophysiology by decreasing
548 O₂ affinity, which in successive turn promotes HbS polymerization, RBC sickling, and
549 hemolysis [125]. As a consequence, the hydrolysis of extracellular ATP and accumulation of
550 adenosine are favoured, and signalling via adenosine receptors may promote deoxygenation of
551 sickle Hb and in turn (HbS) polymerization and RBC sickling.

552 The higher levels of pyroglutamic acid or 5-oxoproline in SS-RBCs compared to
553 healthy counterparts can be attributed to an anomaly in salvage pathway of GSH (Fig. S6a, b).
554 5-oxoproline is acted upon by the 5-oxoprolinase enzyme (ATP-requiring enzyme) to yield
555 glutamate [126]. The conversion of glutamate by the action of two consecutive ATP-dependant
556 enzymes yields back GSH (Fig. 3). However, 5-oxoprolinase exhibited slow and inefficient
557 enzyme activity (reaction rate of 0.45 nmol/h), which may explain the increased levels of 5-
558 oxoproline in the cells[127]. Also, if γ -GCS fails to find an acceptor cysteine during its
559 catalysis, it can autocyclize γ -glutamyl phosphate (intermediate product) to form 5-oxoproline
560 [128].

561 Furthermore, a depleted pool of ATP, cysteine, and glycine due to sickle
562 pathophysiology as discussed above can retard the activity γ -glutamyl cycle enzymes, i.e.,
563 OXP, γ -GCS and GS[129]. Bacchawat et al., proposed a similar futile cycle involving ATP-
564 dependant γ -glutamyl cycle enzymes like γ -GCS and 5-oxoprolinase, leading to rapid depletion
565 of ATP in cystinosis cells per cycle [130].


566 Alternatively, we can also hypothesize an abnormal activity of GGCT enzyme that
567 leads to the accumulation of 5-oxoproline by acting on γ -glutamyl-AA as a response to a
568 decline in the concentration of cellular GSH under oxidative stress. Previous reports showed
569 that GGCT reduces oxidative and osmotic stress in RBCs which prevents deformability
570 prolonging their life span [131]. In various cancers, higher GGCT expression was observed
571 and reported as a therapeutic target [132]. In SS-RBCs, a deregulated GGCT response leads to
572 ATP depletion and also limits the availability of glycine and cysteine, which are GSH
573 precursors [132].

574 5. Conclusion

575

576 In this study, we reported an altered elemental profile of plasma from sickle cell patients and
 577 healthy controls. We observed higher levels of Mg, Zn, Ca, K, and Pb in the plasma of SCD
 578 compared to the control groups which corroborated with frequent hemolysis, rampant
 579 dehydration of SS-RBCs via ion loss through the Gardos channel (due to K^+ loss), and anemia-
 580 induced lead accumulation. Additionally, a steady decrease in plasma Rb/K ratio was observed
 581 for SCD when compared to trait and healthy control. We found that compromised functioning
 582 of γ -glutamyl cycle leading to high levels of oxidative stress was associated with SCD. These data
 583 could be validated in a larger population while taking other clinical parameters into
 584 consideration. This will be useful to gain deeper insight into the biomechanical breakdown of
 585 SS-RBCs at the molecular level and critical for identifying novel therapeutic targets for SCD
 586 patients.

587



588

589

590 **Figure 3. Schematics outlining the biomechanical aberration and oxidative stress leading to**
 591 **inoperable γ -glutamyl cycle in SS-RBCs.** Metabolites in shades of yellow are increased in SS-RBCs
 592 compared to healthy. Metabolites in shades of blue are decreased in SS-RBCs compared to healthy.
 593 Increase in color intensity indicates a higher magnitude. The solid red arrows indicate an altered gamma-
 594 glutamyl cycle; the yellow arrow depicts altered GSH redox cycle; arrows with dashed outline entails an
 595 obstructed metabolic reaction; green arrows/text depicts previously reported pathophysiology of SS-RBCs.
 596 GGCT: gamma-glutamyl cyclotransferase; GGT: gamma-glutamyltranspeptidase; γ -GCS: glutamate
 597 cysteine ligase; GS: glutathione synthase; OXP: 5-oxoprolinase; γ -Glu-Cys-Gly: glutathione; DP:
 598 dipeptidase; HMP: hexose monophosphate pathway; EMP: Embden Meyerhof pathway; ATP:
 599 Adenosine triphosphate; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; Pi:
 600 phosphate.

601

602 **Funding information**

603 SK acknowledges financial support from the University of Delhi (Institution of Eminence grant
604 IOE/FRP/LS/2020/27). SK also acknowledges the financial support from BITS Pilani, K.K. Birla Goa
605 campus (BPGC/RIG/2022-23/09-2022/01; GOA/ACG/2022-2023/Oct/10). RKN acknowledges Core
606 support from the ICGEB New Delhi Component and project support from Department of Biotechnology
607 New Delhi. SB acknowledges Department of Biotechnology, Government of India for Research
608 Fellowship. ASR is thankful to the Government of Odisha for the Biju Patnaik Research Fellowship.
609

610 **Author contributions**

611 Shruti Bhatt: Ideated the study, processed samples, designed and performed the ionomic and
612 metabolomic experiments, analysed and plotted data, prepared the draft of the manuscript.

613 Amit Kumar Mohapatra: Performed ionomic experiments, analysed ionomics data, helped in
614 drafting the manuscript

615 Satyabrata Meher, Apratim Sai Rajesh and Pradip Kumar Panda: Recruitment of participants,
616 clinical profiling, human sample collection, processing and transport

617 Ranjan Kumar Nanda and Suman Kundu: Conceived and supervised the study, analysed data,
618 provided tools and reagents, raised funds and drafted and edited the manuscript.

619 .

620 **Conflicts of interest**

621 The authors declare no conflict of interest.

622

623 **Acknowledgement**

624 Prof. Alo Nag, Department of Biochemistry, University of Delhi South Campus, New Delhi, India, is
625 acknowledged for administrative supervision and scientific discussion with SB. Prof. Bishnu Prasad
626 Dash, Adjunct Professor, ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India is
627 acknowledged for scientific discussion with SB and ASR. Ms. Nidhi Mittal is acknowledged for
628 scientific discussions with SB. Central Instrumentation Facility (CIF), University of Delhi South
629 Campus, New Delhi, India, is appreciated for help with metabolomics data collection. Mr Anil Bhansali,
630 Sai Phytochemicals, New Delhi is appreciated for inspiring the laboratory to investigate sickle cell
631 disease. Dharmender Singh is acknowledged for miscellaneous help to the laboratory.
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655

656 Figure Legends

657

658 **Figure 1. Plasma trace element levels of sickle cell patient (HbSS), sickle cell trait (HbAS) and**
659 **healthy control (HC) and their ratio showed significant differences. a) Mg, b) Fe, c) Ca, d) Zn, e)**
660 **Pb, f) Cu, g) Rb, h) K, i) Se, j) Rb:K. *p < 0.05, **p < 0.01, ***p < 0.001 **** p < 0.0001; HbSS:**
661 **Sickle cell disease; HbAS: Sickle cell trait; HC: Healthy control.**

662 **Figure 2. Perturbed RBC metabolic fingerprint observed in sickle cell disease patients (HbSS)**
663 **compared to the healthy control (HC). a) PCA score plot showed RBC metabolites (n=442) of SCD**
664 **patients cluster away from the healthy controls. b) Volcano plot highlighting the dysregulated**
665 **erythrocyte metabolites in SCD (HbSS) compared to the healthy control (HC). c) Hierarchical**
666 **Clustering representing the distribution of 25 important RBC metabolites in SCD patients and healthy**
667 **controls. Columns correspond to samples, and rows to individual metabolites. The color scale indicates**
668 **the relative abundance of metabolites: red being the most abundant and blue the less abundant**
669 **metabolites. d) Metabolic pathways altered in the RBCs of SCD patients compared to healthy controls.**
670 **The pathway impact values (x-axis) represent the influencing factor of topological analysis, and the –**
671 **log(p) (y-axis) represents the p-value of the pathway enrichment analysis. The vital metabolic pathways**
672 **were defined as having –log(p) > 2 and pathway impact factor > 0.2.**

673

674 **Figure 3. Schematics outlining the biomechanical aberration and oxidative stress leading to**
675 **inoperable γ -glutamyl cycle in SS-RBCs. Metabolites in shades of yellow are increased in SS-RBCs**
676 **compared to healthy. Metabolites in shades of blue are decreased in SS-RBCs compared to healthy.**
677 **Increase in color intensity indicates a higher magnitude. The solid red arrows indicate an altered**
678 **gamma-glutamyl cycle; the yellow arrow depicts altered GSH redox cycle; arrows with dashed outline**
679 **entails an obstructed metabolic reaction; green arrows/text depicts previously reported pathophysiology**
680 **of SS-RBCs.**

681 GGCT: gamma-glutamyl cyclotransferase; GGT: gamma-glutamyltranspeptidase; γ -GCS: glutamate
682 cysteine ligase; GS: glutathione synthase; OXP: 5-oxoprolinase; γ -Glu-Cys-Gly: glutathione; DP:
683 dipeptidase; HMP: hexose monophosphate pathway; EMP: Embden Meyerhof pathway; ATP:
684 Adenosine triphosphate; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; Pi:
685 phosphate.

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760

References

- [1] L. Pauling, H.A. Itano, et al., Sickle cell anemia a molecular disease, *Science* 110(2865) (1949) 543-8.
- [2] S.A. Pereira, S. Brener, C.S. Cardoso, A.B. Proietti, Sickle Cell Disease: quality of life in patients with hemoglobin SS and SC disorders, *Rev Bras Hematol Hemoter* 35(5) (2013) 325-31.
- [3] F.B. Piel, [Sickle-cell disease: geographical distribution and population estimates], *Med Sci (Paris)* 29(11) (2013) 965-7.
- [4] F.B. Piel, M.H. Steinberg, D.C. Rees, Sickle Cell Disease, *N Engl J Med* 376(16) (2017) 1561-1573.
- [5] F.B. Piel, T.N. Williams, Subphenotypes of sickle cell disease in Africa, *Blood* 130(20) (2017) 2157-2158.
- [6] D.C. Rees, T.N. Williams, M.T. Gladwin, Sickle-cell disease, *Lancet* 376(9757) (2010) 2018-31.
- [7] M.K. Safo, O. Abdulmalik, R. Danso-Danquah, J.C. Burnett, S. Nokuri, G.S. Joshi, F.N. Musayev, T. Asakura, D.J. Abraham, Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds, *J Med Chem* 47(19) (2004) 4665-76.
- [8] M.H. Steinberg, Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches, *ScientificWorldJournal* 8 (2008) 1295-324.
- [9] J.F. Bertles, R. Rabinowitz, J. Döbler, Hemoglobin interaction: modification of solid phase composition in the sickling phenomenon, *Science* 169(3943) (1970) 375-7.
- [10] S. Ballas, Sickle cell pain: Second edition, 2015.
- [11] S.K. Ballas, D.S. Darbari, Review/overview of pain in sickle cell disease, *Complement Ther Med* 49 (2020) 102327.
- [12] A. Sanyaolu, E. Agiri, C. Bertram, L. Brookes, J. Choudhury, D. Datt, A. Ibrahim, A. Maciejko, A. Mansfield, J. Nkrumah, M. Williams, Current modalities of sickle cell disease management, *Blood Sci* 2(4) (2020) 109-116.
- [13] P. Sundd, M.T. Gladwin, E.M. Novelli, Pathophysiology of Sickle Cell Disease, *Annu Rev Pathol* 14 (2019) 263-292.
- [14] B.P. Yawn, G.R. Buchanan, A.N. Afenyi-Annan, S.K. Ballas, K.L. Hassell, A.H. James, L. Jordan, S.M. Lanzkron, R. Lottenberg, W.J. Savage, P.J. Tanabe, R.E. Ware, M.H. Murad, J.C. Goldsmith, E. Ortiz, R. Fulwood, A. Horton, J. John-Sowah, Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members, *JAMA* 312(10) (2014) 1033-48.
- [15] H. Tran, M. Gupta, K. Gupta, Targeting novel mechanisms of pain in sickle cell disease, *Blood* 130(22) (2017) 2377-2385.
- [16] D. Lanznaster, D.R. de Assis, P. Corcia, P.F. Pradat, H. Blasco, Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS, *Front Neurol* 9 (2018) 1126.
- [17] X. Hu, M.G. Adebisi, J. Luo, K. Sun, T.T. Le, Y. Zhang, H. Wu, S. Zhao, H. Karmouty-Quintana, H. Liu, A. Huang, Y.E. Wen, O.L. Zaika, M. Mamenko, O.M. Pochynyuk, R.E. Kellems, H.K. Eltzschig, M.R. Blackburn, E.T. Walters, D. Huang, H. Hu, Y. Xia, Sustained Elevated Adenosine via ADORA2B Promotes Chronic Pain through Neuro-immune Interaction, *Cell Rep* 16(1) (2016) 106-119.
- [18] Y. Zhang, V. Berka, A. Song, K. Sun, W. Wang, W. Zhang, C. Ning, C. Li, Q. Zhang, M. Bogdanov, D.C. Alexander, M.V. Milburn, M.H. Ahmed, H. Lin, M. Idowu, J. Zhang, G.J. Kato, O.Y. Abdulmalik, W. Zhang, W. Dowhan, R.E. Kellems, P. Zhang, J. Jin, M. Safo, A.L. Tsai, H.S. Juneja, Y. Xia, Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression, *J Clin Invest* 124(6) (2014) 2750-61.
- [19] A. Kihara, Y. Igarashi, Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720, *Biochim Biophys Acta* 1781(9) (2008) 496-502.
- [20] K. Sun, Y. Zhang, A. D'Alessandro, T. Nemkov, A. Song, H. Wu, H. Liu, M. Adebisi, A. Huang, Y.E. Wen, M.V. Bogdanov, A. Vila, J. O'Brien, R.E. Kellems, W. Dowhan, A.W. Subudhi, S. Jameson-Van Houten, C.G. Julian, A.T. Lovering, M. Safo, K.C. Hansen, R.C. Roach, Y. Xia, Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia, *Nat Commun* 7 (2016) 12086.

- 761 [21] K. Sun, A. D'Alessandro, M.H. Ahmed, Y. Zhang, A. Song, T.P. Ko, T. Nemkov, J.A. Reisz, H. Wu, M.
762 Adebisi, Z. Peng, J. Gong, H. Liu, A. Huang, Y.E. Wen, A.Q. Wen, V. Berka, M.V. Bogdanov, O.
763 Abdulmalik, L. Han, A.L. Tsai, M. Idowu, H.S. Juneja, R.E. Kellems, W. Dowhan, K.C. Hansen, M.K. Safo,
764 Y. Xia, Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic
765 Reprogramming in Sick Cell Disease, *Sci Rep* 7(1) (2017) 15281.
- 766 [22] Y. Xiong, P. Yang, R.L. Proia, T. Hla, Erythrocyte-derived sphingosine 1-phosphate is essential for
767 vascular development, *J Clin Invest* 124(11) (2014) 4823-8.
- 768 [23] H. Wu, M. Bogdanov, Y. Zhang, K. Sun, S. Zhao, A. Song, R. Luo, N.F. Parchim, H. Liu, A. Huang,
769 M.G. Adebisi, J. Jin, D.C. Alexander, M.V. Milburn, M. Idowu, H.S. Juneja, R.E. Kellems, W. Dowhan, Y.
770 Xia, Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell disease, *Sci Rep*
771 6 (2016) 29637.
- 772 [24] S.P. Welch, L.J. Sim-Selley, D.E. Selley, Sphingosine-1-phosphate receptors as emerging targets for
773 treatment of pain, *Biochem Pharmacol* 84(12) (2012) 1551-62.
- 774 [25] H. Liu, M. Adebisi, R.R. Liu, A. Song, J. Manalo, Y.E. Wen, A.Q. Wen, T. Weng, J. Ko, M. Idowu, R.E.
775 Kellems, H.K. Eltzschig, M.R. Blackburn, H.S. Juneja, Y. Xia, Elevated ecto-5'-nucleotidase: a missing
776 pathogenic factor and new therapeutic target for sickle cell disease, *Blood Adv* 2(15) (2018) 1957-
777 1968.
- 778 [26] K. Sun, Y. Zhang, M.V. Bogdanov, H. Wu, A. Song, J. Li, W. Dowhan, M. Idowu, H.S. Juneja, J.G.
779 Molina, M.R. Blackburn, R.E. Kellems, Y. Xia, Elevated adenosine signaling via adenosine A2B receptor
780 induces normal and sickle erythrocyte sphingosine kinase 1 activity, *Blood* 125(10) (2015) 1643-52.
- 781 [27] Y. Zhang, Y. Dai, J. Wen, W. Zhang, A. Grenz, H. Sun, L. Tao, G. Lu, D.C. Alexander, M.V. Milburn,
782 L. Carter-Dawson, D.E. Lewis, W. Zhang, H.K. Eltzschig, R.E. Kellems, M.R. Blackburn, H.S. Juneja, Y. Xia,
783 Detrimental effects of adenosine signaling in sickle cell disease, *Nat Med* 17(1) (2011) 79-86.
- 784 [28] D. Darghouth, B. Koehl, G. Madalinski, J.F. Heilier, P. Bovee, Y. Xu, M.F. Olivier, P. Bartolucci, M.
785 Benkerrou, S. Pissard, Y. Colin, F. Galacteros, G. Bosman, C. Junot, P.H. Romeo, Pathophysiology of
786 sickle cell disease is mirrored by the red blood cell metabolome, *Blood* 117(6) (2011) e57-66.
- 787 [29] K.C. Dembele, T. Mintz, C. Veyrat-Durebex, F. Chabrun, S. Chupin, L. Tessier, G. Simard, D. Henrion,
788 D. Mirebeau-Prunier, J.M. Chao de la Barca, P.L. Tharaux, P. Reynier, Metabolomic Profiling of Plasma
789 and Erythrocytes in Sick Mice Points to Altered Nociceptive Pathways, *Cells* 9(6) (2020).
- 790 [30] K.C. Dembele, C. Veyrat-Durebex, G. Aldiouma, S. Chupin, L. Tessier, Y. Goita, M.A. Baraika, M.
791 Diallo, B.A. Toure, C. Homedan, D. Mirebeau-Prunier, G. Simard, D. Diallo, B.M. Cisse, P. Reynier, J.M.
792 Chao de la Barca, Sick Cell Disease: Metabolomic Profiles of Vaso-Occlusive Crisis in Plasma and
793 Erythrocytes, *J Clin Med* 9(4) (2020).
- 794 [31] I. Subramanian, S. Verma, S. Kumar, A. Jere, K. Anamika, Multi-omics Data Integration,
795 Interpretation, and Its Application, *Bioinform Biol Insights* 14 (2020) 1177932219899051.
- 796 [32] M.H. Antonelou, A.G. Kriebardis, I.S. Papassideri, Aging and death signalling in mature red cells:
797 from basic science to transfusion practice, *Blood Transfus* 8 Suppl 3(Suppl 3) (2010) s39-47.
- 798 [33] A. Bogdanova, A. Makhro, J. Wang, P. Lipp, L. Kaestner, Calcium in red blood cells-a perilous
799 balance, *Int J Mol Sci* 14(5) (2013) 9848-72.
- 800 [34] R. Hasanato, Alterations in serum levels of copper, zinc, and selenium among children with sickle
801 cell anemia, *Turk J Med Sci* 49(5) (2019) 1287-1291.
- 802 [35] M. Khurana, E.B. Fung, E.P. Vichinsky, E.C. Theil, Dietary nonheme iron is equally bioavailable from
803 ferritin or ferrous sulfate in thalassemia intermedia, *Pediatr Hematol Oncol* 34(8) (2017) 455-467.
- 804 [36] N.A. Sopko, H. Matsui, J.L. Hannan, D. Berkowitz, H.C. Champion, L.L. Hsu, B. Musicki, A.L. Burnett,
805 T.J. Bivalacqua, Subacute Hemolysis in Sick Cell Mice Causes Priapism Secondary to NO Imbalance
806 and PDE5 Dysregulation, *J Sex Med* 12(9) (2015) 1878-85.
- 807 [37] S.C. Wilschefski, M.R. Baxter, Inductively Coupled Plasma Mass Spectrometry: Introduction to
808 Analytical Aspects, *Clin Biochem Rev* 40(3) (2019) 115-133.
- 809 [38] R. Culp-Hill, A.J. Srinivasan, S. Gehrke, R. Kamyszek, A. Ansari, N. Shah, I. Welsby, A. D'Alessandro,
810 Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism,
811 *Transfusion* 58(12) (2018) 2797-2806.

- 812 [39] A. D'Alessandro, S.M. Nouraie, Y. Zhang, F. Cendali, F. Gamboni, J.A. Reisz, X. Zhang, K.W. Bartsch,
813 M.D. Galbraith, V.R. Gordeuk, M.T. Gladwin, In vivo evaluation of the effect of sickle cell hemoglobin
814 S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction, *Am J*
815 *Hematol* (2023).
- 816 [40] S.R. Goodman, B.S. Pace, K.C. Hansen, A. D'Alessandro, Y. Xia, O. Daescu, S.J. Glatt, Minireview:
817 Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to
818 precision medicine, *Exp Biol Med* (Maywood) 241(7) (2016) 772-81.
- 819 [41] A.L. Okwi, M. Ocaido, W. Byarugaba, C.M. Ndugwa, A. Parkes, Sickling and solubility tests and the
820 peripheral blood film method for screening for sickle cell disease. [corrected], *S Afr Med J* 99(12)
821 (2009) 887-91.
- 822 [42] T. Sana, S. Fischer, S.J.A.T. Clara, Maximizing metabolite extraction for comprehensive
823 metabolomics studies of erythrocytes, (2007) 5989-7407EN.
- 824 [43] Z. Pang, G. Zhou, J. Ewald, L. Chang, O. Hacariz, N. Basu, J. Xia, Using MetaboAnalyst 5.0 for LC-
825 HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics
826 data, *Nat Protoc* 17(8) (2022) 1735-1761.
- 827 [44] M.A. Rizvi, Z. Hussain, F. Ali, A. Amin, S.H. Mir, G. Rydzek, R.M. Jagtap, S.K. Pardeshi, R.A. Qadri,
828 K. Ariga, Bioactive supra decorated thiazolidine-4-carboxylic acid derivatives attenuate cellular
829 oxidative stress by enhancing catalase activity, *Phys Chem Chem Phys* 22(15) (2020) 7942-7951.
- 830 [45] G. Bosman, Disturbed Red Blood Cell Structure and Function: An Exploration of the Role of Red
831 Blood Cells in Neurodegeneration, *Front Med* (Lausanne) 5 (2018) 198.
- 832 [46] E. Szczesny-Malysiak, J. Dybas, A. Blat, K. Bulat, K. Kus, M. Kaczmarska, A. Wajda, K. Malek, S.
833 Chlopicki, K.M. Marzec, Irreversible alterations in the hemoglobin structure affect oxygen binding in
834 human packed red blood cells, *Biochim Biophys Acta Mol Cell Res* 1867(11) (2020) 118803.
- 835 [47] G. Tomaiuolo, Biomechanical properties of red blood cells in health and disease towards
836 microfluidics, *Biomicrofluidics* 8(5) (2014) 051501.
- 837 [48] N. Cilek, E. Ugurel, E. Goksel, O. Yalcin, Signaling mechanisms in red blood cells: A view through
838 the protein phosphorylation and deformability, *J Cell Physiol* (2023).
- 839 [49] H. Li, G. Lykotrafitis, Erythrocyte membrane model with explicit description of the lipid bilayer
840 and the spectrin network, *Biophys J* 107(3) (2014) 642-653.
- 841 [50] V. Pretini, M.H. Koenen, L. Kaestner, M. Fens, R.M. Schiffelers, M. Bartels, R. Van Wijk, Red Blood
842 Cells: Chasing Interactions, *Front Physiol* 10 (2019) 945.
- 843 [51] S.L. Spitalnik, D.V. Devine, Translating red cell "omics" into new perspectives in transfusion
844 medicine: mining the gems in the data mountains, *Transfusion* 59(1) (2019) 2-5.
- 845 [52] C. Tang, Q. Meng, K. Zhang, T. Zhan, Q. Zhao, S. Zhang, J. Zhang, Multi-omics analyses of red blood
846 cell reveal antioxidation mechanisms associated with hemolytic toxicity of gossypol, *Oncotarget* 8(61)
847 (2017) 103693-103709.
- 848 [53] A. Iolascon, I. Andolfo, R. Russo, Advances in understanding the pathogenesis of red cell
849 membrane disorders, *Br J Haematol* 187(1) (2019) 13-24.
- 850 [54] M. Cascella, S. Vaqar, *Hypermagnesemia*, StatPearls, Treasure Island (FL), 2023.
- 851 [55] A.O. Olukoga, H.O. Adewoye, R.T. Erasmus, M.A. Adedoyin, Erythrocyte and plasma magnesium
852 in sickle-cell anaemia, *East Afr Med J* 67(5) (1990) 348-54.
- 853 [56] A.O. Olukoga, R.T. Erasmus, H.O. Adewoye, Erythrocyte and plasma magnesium status in
854 Nigerians with diabetes mellitus, *Ann Clin Biochem* 26 (Pt 1) (1989) 74-7.
- 855 [57] C. Antwi-Boasiako, Y.A. Kusi-Mensah, C. Hayfron-Benjamin, R. Aryee, G.B. Dankwah, L.A.
856 Kwawukume, E.O. Darkwa, Total Serum Magnesium Levels and Calcium-To-Magnesium Ratio in Sickle
857 Cell Disease, *Medicina* (Kaunas) 55(9) (2019).
- 858 [58] O.O. Yousif, M.K. Hassan, L.M. Al-Naama, Red Blood Cell and Serum Magnesium Levels Among
859 Children and Adolescents With Sickle Cell Anemia, *Biol Trace Elem Res* 186(2) (2018) 295-304.
- 860 [59] B.F. Cameron, P. Smariga, Calcium exchange and calcium-related effects in normal and sickle cell
861 anemia erythrocytes, *Prog Clin Biol Res* 20 (1978) 105-22.

- 862 [60] V. Malinovska, P. Matonoha, V. D'Andrea, L. Malinovsky, A. Zechmeister, The role of calcium in
863 the effect of stress hormones, *Cas Lek Cesk* 130(22-23) (1991) 631-4.
- 864 [61] E. Nur, B.J. Biemond, H.M. Otten, D.P. Brandjes, J.J. Schnog, C.S. Group, Oxidative stress in sickle
865 cell disease; pathophysiology and potential implications for disease management, *Am J Hematol* 86(6)
866 (2011) 484-9.
- 867 [62] L. Hertz, R. Huisjes, E. Llaudet-Planas, P. Petkova-Kirova, A. Makhro, J.G. Danielczok, S. Egee, M.
868 Del Mar Manu-Pereira, R. van Wijk, J.L. Vives Corrons, A. Bogdanova, L. Kaestner, Is Increased
869 Intracellular Calcium in Red Blood Cells a Common Component in the Molecular Mechanism Causing
870 Anemia?, *Front Physiol* 8 (2017) 673.
- 871 [63] C. Brugnara, L. de Franceschi, S.L. Alper, Inhibition of Ca(2+)-dependent K⁺ transport and cell
872 dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives, *J Clin Invest* 92(1)
873 (1993) 520-6.
- 874 [64] C. Brugnara, D.C. Tosteson, Inhibition of K transport by divalent cations in sickle erythrocytes,
875 *Blood* 70(6) (1987) 1810-5.
- 876 [65] E. Nader, M. Romana, P. Connes, The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell
877 Disease, *Front Immunol* 11 (2020) 454.
- 878 [66] V. Barodka, J.G. Mohanty, A.K. Mustafa, L. Santhanam, A. Nyhan, A.K. Bhunia, G. Sikka, D. Nyhan,
879 D.E. Berkowitz, J.M. Rifkind, Nitroprusside inhibits calcium-induced impairment of red blood cell
880 deformability, *Transfusion* 54(2) (2014) 434-44.
- 881 [67] C. Antwi-Boasiako, Y.A. Kusi-Mensah, C. Hayfron-Benjamin, R. Aryee, G.B. Dankwah, K.L. Abla, E.
882 Owusu Darkwa, F.A. Botchway, E. Sampene-Donkor, Serum Potassium, Sodium, and Chloride Levels in
883 Sickle Cell Disease Patients and Healthy Controls: A Case-Control Study at Korle-Bu Teaching Hospital,
884 Accra, *Biomark Insights* 14 (2019) 1177271919873889.
- 885 [68] S. Pandey, A. Sharma, S. Dahia, V. Shah, V. Sharma, R.M. Mishra, S. Pandey, R. Saxena, Biochemical
886 indicator of sickle cell disease: preliminary report from India, *Indian J Clin Biochem* 27(2) (2012) 191-
887 5.
- 888 [69] C.T. Noguchi, A.N. Schechter, G.P. Rodgers, Sickle cell disease pathophysiology, *Baillieres Clin*
889 *Haematol* 6(1) (1993) 57-91.
- 890 [70] D. Manwani, P.S. Frenette, Vaso-occlusion in sickle cell disease: pathophysiology and novel
891 targeted therapies, *Blood* 122(24) (2013) 3892-8.
- 892 [71] J.R. Aluoch, Renal and electrolyte profile in steady state sickle cell disease: observations in
893 patients with sickle cell disease in The Netherlands, *Trop Geogr Med* 41(2) (1989) 128-32.
- 894 [72] J.R. Asirvatham, V. Moses, L. Bjornson, Errors in potassium measurement: a laboratory
895 perspective for the clinician, *N Am J Med Sci* 5(4) (2013) 255-9.
- 896 [73] S. Tomlinson, P.D. Mathialagan, S.K. Maloney, Special K: testing the potassium link between
897 radioactive rubidium (⁸⁶Rb) turnover and metabolic rate, *J Exp Biol* 217(Pt 7) (2014) 1040-5.
- 898 [74] H.L. Meltzer, R.M. Taylor, S.R. Platmann, R.R. Fieve, Rubidium: a potential modifier of affect and
899 behaviour, *Nature* 223(5203) (1969) 321-2.
- 900 [75] N. Rahimi, M. Hassanipour, F. Yarmohammadi, H. Faghir-Ghanesefat, N. Pourshadi, E.
901 Bahramnejad, A.R. Dehpour, Nitric oxide and glutamate are contributors of anti-seizure activity of
902 rubidium chloride: A comparison with lithium, *Neurosci Lett* 708 (2019) 134349.
- 903 [76] L. Xiao, G. Zan, J. Qin, X. Wei, G. Lu, X. Li, H. Zhang, Y. Zou, L. Yang, M. He, Z. Zhang, X. Yang,
904 Combined exposure to multiple metals and cognitive function in older adults, *Ecotoxicol Environ Saf*
905 222 (2021) 112465.
- 906 [77] N. Kordjazy, A. Haj-Mirzaian, S. Amiri, S. Ostadhadi, M. Kordjazy, M. Sharifzadeh, A.R. Dehpour,
907 Elevated level of nitric oxide mediates the anti-depressant effect of rubidium chloride in mice, *Eur J*
908 *Pharmacol* 762 (2015) 411-8.
- 909 [78] S. Martin, M.C. Roderick, C. Abel, P. Wolters, M.A. Toledo-Tamula, C. Fitzhugh, M. Hsieh, J. Tisdale,
910 Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and
911 comparison with unaffected siblings, *Neuropsychol Rehabil* 30(9) (2020) 1666-1681.

- 912 [79] C.T. Hijmans, K. Fijnvandraat, M.A. Grootenhuys, N. van Geloven, H. Heijboer, M. Peters, J.
913 Oosterlaan, Neurocognitive deficits in children with sickle cell disease: a comprehensive profile,
914 *Pediatr Blood Cancer* 56(5) (2011) 783-8.
- 915 [80] S.K. Ballas, Neurocognitive complications of sickle cell anemia in adults, *JAMA* 303(18) (2010)
916 1862-3.
- 917 [81] L.O. Matondo, E. Kija, K.P. Manji, Neurocognitive Functioning among Children with Sickle Cell
918 Anemia Attending SCA Clinic at MNH, Dar es Salaam, Tanzania, *Neurol Res Int* 2020 (2020) 3636547.
- 919 [82] N.S. Green, D. Munube, P. Bangirana, L.R. Buluma, B. Kebirungi, R. Opoka, E. Mupere, P. Kasirye,
920 S. Kiguli, A. Birabwa, M.S. Kawooya, S.K. Lubowa, R. Sekibira, E. Kayongo, H. Hume, M. Elkind, W. Peng,
921 G. Li, C. Rosano, P. LaRussa, F.J. Minja, A. Boehme, R. Idro, Burden of neurological and neurocognitive
922 impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study, *BMC*
923 *Pediatr* 19(1) (2019) 381.
- 924 [83] A.A. Hegazy, M.M. Zaher, M.A. Abd El-Hafez, A.A. Morsy, R.A. Saleh, Relation between anemia
925 and blood levels of lead, copper, zinc and iron among children, *BMC Res Notes* 3 (2010) 133.
- 926 [84] M.M. Lubran, Lead toxicity and heme biosynthesis, *Ann Clin Lab Sci* 10(5) (1980) 402-13.
- 927 [85] J. Schwartz, P.J. Landrigan, E.L. Baker, Jr., W.A. Orenstein, I.H. von Lindern, Lead-induced anemia:
928 dose-response relationships and evidence for a threshold, *Am J Public Health* 80(2) (1990) 165-8.
- 929 [86] C.G. Drossos, K.T. Mavroidis, Z. Papadopoulou-Daifotis, D.N. Michalodimitrakis, L.X. Salamalikis,
930 A.K. Gounaris, D.D. Varonos, Environmental lead pollution in Greece, *Am Ind Hyg Assoc J* 43(10) (1982)
931 796-8.
- 932 [87] I.H. Elkhidir, S.S. Ali, W.K. Ali, H.R. Madani, R.A. Basheir, R.M. Altayeb, R.H.S. Shazali, S.
933 Fadlelmoula, W.M. Eltayeb, Z.I. Omar, M. Elnil, S.O.O. Mohamed, Zinc, Magnesium, and Copper Levels
934 in Patients with Sickle Cell Disease: A Systematic Review and Meta-analysis, *Avicenna J Med* 12(2)
935 (2022) 45-53.
- 936 [88] A. Ece, B.S. Uyanik, A. Iscan, P. Ertan, M.R. Yigitoglu, Increased serum copper and decreased serum
937 zinc levels in children with iron deficiency anemia, *Biol Trace Elem Res* 59(1-3) (1997) 31-9.
- 938 [89] S. Turgut, A. Polat, M. Inan, G. Turgut, G. Emmungil, M. Bican, T.Y. Karakus, O. Genc, Interaction
939 between anemia and blood levels of iron, zinc, copper, cadmium and lead in children, *Indian J Pediatr*
940 74(9) (2007) 827-30.
- 941 [90] I.J. Newhouse, D.B. Clement, C. Lai, Effects of iron supplementation and discontinuation on serum
942 copper, zinc, calcium, and magnesium levels in women, *Med Sci Sports Exerc* 25(5) (1993) 562-71.
- 943 [91] H.C. Kim, N.P. Dugan, J.H. Silber, M.B. Martin, E. Schwartz, K. Ohene-Frempong, A.R. Cohen,
944 Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell
945 disease, *Blood* 83(4) (1994) 1136-42.
- 946 [92] K.R. Rao, A.R. Patel, P. McGinnis, M.K. Patel, Iron stores in adults with sickle cell anemia, *J Lab Clin*
947 *Med* 103(5) (1984) 792-7.
- 948 [93] L. Flohe, W.A. Gunzler, H.H. Schock, Glutathione peroxidase: a selenoenzyme, *FEBS Lett* 32(1)
949 (1973) 132-4.
- 950 [94] J.T. Rotruck, A.L. Pope, H.E. Ganther, A.B. Swanson, D.G. Hafeman, W.G. Hoekstra, Selenium:
951 biochemical role as a component of glutathione peroxidase, *Science* 179(4073) (1973) 588-90.
- 952 [95] S. Li, W. Sun, K. Zhang, J. Zhu, X. Jia, X. Guo, Q. Zhao, C. Tang, J. Yin, J. Zhang, Selenium deficiency
953 induces spleen pathological changes in pigs by decreasing selenoprotein expression, evoking oxidative
954 stress, and activating inflammation and apoptosis, *J Anim Sci Biotechnol* 12(1) (2021) 65.
- 955 [96] G.F. Combs, Jr., W.P. Gray, Chemopreventive agents: selenium, *Pharmacol Ther* 79(3) (1998) 179-
956 92.
- 957 [97] R. Irons, B.A. Carlson, D.L. Hatfield, C.D. Davis, Both selenoproteins and low molecular weight
958 selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein
959 expression, *J Nutr* 136(5) (2006) 1311-7.
- 960 [98] R. Scott, A. MacPherson, R.W. Yates, B. Hussain, J. Dixon, The effect of oral selenium
961 supplementation on human sperm motility, *Br J Urol* 82(1) (1998) 76-80.

- 962 [99] M.P. Look, J.K. Rockstroh, G.S. Rao, K.A. Kreuzer, S. Barton, H. Lemoch, T. Sudhop, J. Hoch, K.
963 Stockinger, U. Spengler, T. Sauerbruch, Serum selenium, plasma glutathione (GSH) and erythrocyte
964 glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human
965 immunodeficiency virus-1 (HIV-1)-infection, *Eur J Clin Nutr* 51(4) (1997) 266-72.
- 966 [100] L. Kiremidjian-Schumacher, M. Roy, Effect of selenium on the immunocompetence of patients
967 with head and neck cancer and on adoptive immunotherapy of early and established lesions,
968 *Biofactors* 14(1-4) (2001) 161-8.
- 969 [101] C.R. Morris, J.H. Suh, W. Hagar, S. Larkin, D.A. Bland, M.H. Steinberg, E.P. Vichinsky, M.
970 Shigenaga, B. Ames, F.A. Kuypers, E.S. Klings, Erythrocyte glutamine depletion, altered redox
971 environment, and pulmonary hypertension in sickle cell disease, *Blood* 111(1) (2008) 402-10.
- 972 [102] S.R. Goodman, The irreversibly sickled cell: a perspective, *Cell Mol Biol (Noisy-le-grand)* 50(1)
973 (2004) 53-8.
- 974 [103] M. Aslan, D. Thornley-Brown, B.A. Freeman, Reactive species in sickle cell disease, *Ann N Y Acad*
975 *Sci* 899 (2000) 375-91.
- 976 [104] F.Q. Schafer, G.R. Buettner, Redox environment of the cell as viewed through the redox state of
977 the glutathione disulfide/glutathione couple, *Free Radic Biol Med* 30(11) (2001) 1191-212.
- 978 [105] M.C. Garel, C. Domenget, J. Caburi-Martin, C. Prehu, F. Galacteros, Y. Beuzard, Covalent binding
979 of glutathione to hemoglobin. I. Inhibition of hemoglobin S polymerization, *J Biol Chem* 261(31) (1986)
980 14704-9.
- 981 [106] M. Reid, A. Badaloo, T. Forrester, F. Jahoor, In vivo rates of erythrocyte glutathione synthesis in
982 adults with sickle cell disease, *Am J Physiol Endocrinol Metab* 291(1) (2006) E73-9.
- 983 [107] R. Franco, O.J. Schoneveld, A. Pappa, M.I. Panayiotidis, The central role of glutathione in the
984 pathophysiology of human diseases, *Arch Physiol Biochem* 113(4-5) (2007) 234-58.
- 985 [108] J.E. Snoke, K. Bloch, Studies on the mechanism of action of glutathione synthetase, *J Biol Chem*
986 213(2) (1955) 825-35.
- 987 [109] S.C. Rogers, A. Said, D. Corcuera, D. McLaughlin, P. Kell, A. Doctor, Hypoxia limits antioxidant
988 capacity in red blood cells by altering glycolytic pathway dominance, *FASEB J* 23(9) (2009) 3159-70.
- 989 [110] W.G. Siems, O. Sommerburg, T. Grune, Erythrocyte free radical and energy metabolism, *Clin*
990 *Nephrol* 53(1 Suppl) (2000) S9-17.
- 991 [111] P.S. Low, P. Rathinavelu, M.L. Harrison, Regulation of glycolysis via reversible enzyme binding to
992 the membrane protein, band 3, *J Biol Chem* 268(20) (1993) 14627-31.
- 993 [112] I. Messana, M. Orlando, L. Cassiano, L. Pennacchietti, C. Zuppi, M. Castagnola, B. Giardina,
994 Human erythrocyte metabolism is modulated by the O₂-linked transition of hemoglobin, *FEBS Lett*
995 390(1) (1996) 25-8.
- 996 [113] D. Sterling, R.A. Reithmeier, J.R. Casey, A transport metabolon. Functional interaction of carbonic
997 anhydrase II and chloride/bicarbonate exchangers, *J Biol Chem* 276(51) (2001) 47886-94.
- 998 [114] L.J. Bruce, R. Beckmann, M.L. Ribeiro, L.L. Peters, J.A. Chasis, J. Delaunay, N. Mohandas, D.J.
999 Anstee, M.J. Tanner, A band 3-based macrocomplex of integral and peripheral proteins in the RBC
1000 membrane, *Blood* 101(10) (2003) 4180-8.
- 1001 [115] N.N. Barvitenko, N.C. Adragna, R.E. Weber, Erythrocyte signal transduction pathways, their
1002 oxygenation dependence and functional significance, *Cell Physiol Biochem* 15(1-4) (2005) 1-18.
- 1003 [116] M.E. Campanella, H. Chu, P.S. Low, Assembly and regulation of a glycolytic enzyme complex on
1004 the human erythrocyte membrane, *Proc Natl Acad Sci U S A* 102(7) (2005) 2402-7.
- 1005 [117] H. Chu, P.S. Low, Mapping of glycolytic enzyme-binding sites on human erythrocyte band 3,
1006 *Biochem J* 400(1) (2006) 143-51.
- 1007 [118] H. Chu, A. Breite, P. Ciruolo, R.S. Franco, P.S. Low, Characterization of the deoxyhemoglobin
1008 binding site on human erythrocyte band 3: implications for O₂ regulation of erythrocyte properties,
1009 *Blood* 111(2) (2008) 932-8.
- 1010 [119] B.S. Kirby, G. Hanna, H.C. Hendargo, T.J. McMahan, Restoration of intracellular ATP production
1011 in banked red blood cells improves inducible ATP export and suppresses RBC-endothelial adhesion,
1012 *Am J Physiol Heart Circ Physiol* 307(12) (2014) H1737-44.

- 1013 [120] S.C. Rogers, J.G. Ross, A. d'Avignon, L.B. Gibbons, V. Gazit, M.N. Hassan, D. McLaughlin, S. Griffin,
1014 T. Neumayr, M. Debaun, M.R. DeBaun, A. Doctor, Sickle hemoglobin disturbs normal coupling among
1015 erythrocyte O₂ content, glycolysis, and antioxidant capacity, *Blood* 121(9) (2013) 1651-62.
- 1016 [121] E. Ferru, K. Giger, A. Pantaleo, E. Campanella, J. Grey, K. Ritchie, R. Vono, F. Turrini, P.S. Low,
1017 Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3,
1018 *Blood* 117(22) (2011) 5998-6006.
- 1019 [122] R.L. Sabina, N.J. Wandersee, C.A. Hillery, Ca²⁺-CaM activation of AMP deaminase contributes to
1020 adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle
1021 erythrocytes, *Br J Haematol* 144(3) (2009) 434-45.
- 1022 [123] M.F. Leal Denis, J.J. Incicco, M.V. Espelt, S.V. Verstraeten, O.P. Pignataro, E.R. Lazarowski, P.J.
1023 Schwarzbaum, Kinetics of extracellular ATP in mastoparan 7-activated human erythrocytes, *Biochim*
1024 *Biophys Acta* 1830(10) (2013) 4692-707.
- 1025 [124] B.S. Kirby, M.A. Sparks, E.R. Lazarowski, D.A. Lopez Domowicz, H. Zhu, T.J. McMahon, Pannexin
1026 1 channels control the hemodynamic response to hypoxia by regulating O₂-sensitive extracellular
1027 ATP in blood, *Am J Physiol Heart Circ Physiol* 320(3) (2021) H1055-H1065.
- 1028 [125] H. Zhu, R. Zennadi, B.X. Xu, J.P. Eu, J.A. Torok, M.J. Telen, T.J. McMahon, Impaired adenosine-5'-
1029 triphosphate release from red blood cells promotes their adhesion to endothelial cells: a mechanism
1030 of hypoxemia after transfusion, *Crit Care Med* 39(11) (2011) 2478-86.
- 1031 [126] P. Van der Werf, M. Orłowski, A. Meister, Enzymatic conversion of 5-oxo-L-proline (L-pyrrolidone
1032 carboxylate) to L-glutamate coupled with cleavage of adenosine triphosphate to adenosine
1033 diphosphate, a reaction in the -glutamyl cycle, *Proc Natl Acad Sci U S A* 68(12) (1971) 2982-5.
- 1034 [127] M. Watanabe, M. Kusano, A. Oikawa, A. Fukushima, M. Noji, K. Saito, Physiological roles of the
1035 beta-substituted alanine synthase gene family in Arabidopsis, *Plant Physiol* 146(1) (2008) 310-20.
- 1036 [128] J.J. Abbott, J. Pei, J.L. Ford, Y. Qi, V.N. Grishin, L.A. Pitcher, M.A. Phillips, N.V. Grishin, Structure
1037 prediction and active site analysis of the metal binding determinants in gamma -glutamylcysteine
1038 synthetase, *J Biol Chem* 276(45) (2001) 42099-107.
- 1039 [129] P.G. Richman, A. Meister, Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric
1040 feedback inhibition by glutathione, *J Biol Chem* 250(4) (1975) 1422-6.
- 1041 [130] A.K. Bachhawat, S. Yadav, The glutathione cycle: Glutathione metabolism beyond the gamma-
1042 glutamyl cycle, *IUBMB Life* 70(7) (2018) 585-592.
- 1043 [131] Z. He, X. Sun, S. Wang, D. Bai, X. Zhao, Y. Han, P. Hao, X.S. Liu, Ggct (gamma-glutamyl
1044 cyclotransferase) plays an important role in erythrocyte antioxidant defense and red blood cell
1045 survival, *Br J Haematol* 195(2) (2021) 267-275.
- 1046 [132] S. Kageyama, E. Hanada, H. Ii, K. Tomita, T. Yoshiki, A. Kawauchi, Gamma-
1047 Glutamylcyclotransferase: A Novel Target Molecule for Cancer Diagnosis and Treatment, *Biomed Res*
1048 *Int* 2015 (2015) 345219.

1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065

1066 **List of Abbreviation**

1067	
1068	SCD, Sickle cell disease
1069	ICP-MS, Inductively coupled plasma mass spectrometry
1070	LC-MS, Liquid chromatography-mass spectrometry
1071	RBC, Red blood cell
1072	SS-RBCs, sickle shaped RBCs (SS-RBCs)
1073	WHO, World health organisation
1074	VOC, Vaso-occlusive crisis
1075	Hb, hemoglobin
1076	HbA, adult hemoglobin
1077	HbS, sickle cell hemoglobin
1078	HbF, Fetal hemoglobin
1079	VOC, Vaso-Occlusive crisis
1080	QoL, quality of life
1081	HSCT, hematopoietic stem cell transplantation
1082	O ₂ , Oxygen
1083	HbS-O ₂ , Oxygenated sickle hemoglobin
1084	p50, the pressure at which hemoglobin is 50% saturated
1085	ROS, reactive oxygen species
1086	pO ₂ , partial pressure of oxygen
1087	Tg, Transgenic
1088	ADORA2B, Adenosine A2b Receptor
1089	S1P, sphingosine-1-phosphate (S1P)
1090	EMP, Embden Meyerhoff pathway
1091	HMP, Hexose monophosphate pathway
1092	2, 3-DPG, 2,3 Diphosphoglyceric Acid
1093	2, 3-BPG, 2, 3 Bisphosphoglyceric acid
1094	S1PR1, S1P receptor 1
1095	SphK1, Sphingosine Kinase-1
1096	ADA, Adenosine deaminase deficiency
1097	PEG-ADA, Polyethylene glycol-modified adenosine deaminase
1098	CD73, ecto-5'-nucleotidase
1099	CAR, Central African Republic (BAN or CAR)
1100	CAM, Cameroon
1101	BEN, Benin
1102	SEN, Senegal
1103	ARB/AI, Arab-Indian
1104	HbSS, Homozygous sickle cell disease/Sickle cell disease
1105	HbAS, Hetrozygous sickle cell trait/ Sickle cell trait
1106	HbAA, Homozygous normal/ Healthy control
1107	HC, Healthy control
1108	CBC, Complete blood count
1109	PCR, Polymerase chain reaction
1110	HPLC, High performance liquid chromatography
1111	HCD, Higher-energy C-trap dissociation
1112	OPLS-DA, orthogonal projections to latent structures discriminant analysis
1113	FDR, false discovery rate
1114	PCA, principal component analysis
1115	SVM, Linear support vector machine

1116 MCCV, Monte-Carlo cross-validation
1117 ROC, receiver operating characteristic
1118 AUROC, Area under ROC
1119 H₂O₂, Hydrogen peroxide
1120 HNO₃, Nitric acid
1121 N₂, Nitrogen
1122 ²⁴Mg, Magnesium
1123 ⁴⁴Ca, Calcium
1124 ⁵⁷Fe, Iron
1125 ⁶³Cu, Copper
1126 ⁶⁶Zn, Zinc
1127 ⁷⁷Se, Selenium
1128 ⁸⁵Rb, Rubidium
1129 ²⁰⁸Pb, Lead
1130 ³⁹K, Potassium
1131 Hb-O₂, oxyhemoglobin
1132 KCC1/3/4, K-Cl co-transporter
1133 IQ, Intelligent quotient,
1134 BLL, Blood lead level
1135 HCT, Hematocrit
1136 HGB, Hemoglobin (g/dl)
1137 MCHC, Mean corpuscular hemoglobin concentration
1138 NADPH, Nicotinamide adenine dinucleotide phosphate
1139 GSH, reduced glutathione
1140 GSSG, oxidized (GSSG)
1141 G-Hb, glutathiol-hemoglobin
1142 DPT, dipeptidases (DPT)
1143 GGCS, gamma-glutamylcysteine synthetase (G-GCS)
1144 γ-GCT/GGCT, gamma-glutamyl cyclotransferase (G-GCT)
1145 OXP, oxoprolinase
1146 GGT, gamma-glutamyl transpeptidase
1147 ATP, Adenosine triphosphate
1148 cdB3, Band 3
1149 γ-GCS/GGCS, gamma-glutamylcysteine synthetase
1150 GS, GSH sythetase
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165

1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182